Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Scleros...
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: Yahoo! Finance
therapy, CM-101, for the treatment of primary sclerosing cholangitis (PSC), a rare liver disease. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC, and the company's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. According to Dr. Christopher Bowlus, a SPRING trial investigator, 'CM-101 has the potential to change the lives of patients with PSC by reducing fibrosis and cholestasis, which should lead to improved outcomes. CM-101 may also provide patients with relief of symptoms.' The trial demonstrated that CM-101 was well-tolerated and had a safety profile comparable to placebo, and it showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects in patients with PSC. Specifically, CM-101 improved liver stiffness, ELF scores, PRO-C3, liver biochemistries, and bilirubin levels, and reduced pruritus (itch) in patients with PSC. The company plans to meet with the FDA before th
Show less
Read more
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing CholangitisGlobeNewswire
- Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.MarketBeat
- Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business UpdateGlobeNewswire
CMMB
Sec Filings
- 11/21/24 - Form SC
- 11/18/24 - Form 6-K
- 11/15/24 - Form 424B5
- CMMB's page on the SEC website